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In skeletal muscle differentiation, muscle-specific
genes are regulated by two groups of transcription
factors, the MyoD and MEF2 families, which work
together to drive the differentiation process. Here,
we show that ERK5 regulates muscle cell fusion
through Klf transcription factors. The inhibition of
ERK5 activity suppresses muscle cell fusion with
minimal effects on the expression of MyoD, MEF2,
and their target genes. Promoter analysis coupled
to microarray assay reveals that Klf-binding motifs
are highly enriched in the promoter regions of
ERK5-dependent upregulated genes. Remarkably,
Klf2 and Klf4 expression are also upregulated during
differentiation in an ERK5-dependent manner, and
knockdown of Klf2 or Klf4 specifically suppresses
muscle cell fusion. Moreover, we show that Sp1
transcription factor links ERK5 to Klf2/4, and that
nephronectin, a Klf transcriptional target, is involved
in muscle cell fusion. Therefore, an ERK5/Sp1/Klf
module plays a key role in the fusion process during
skeletal muscle differentiation.
INTRODUCTION
The regulation of skeletal muscle formation, termedmyogenesis,
is prerequisite for normal development as well as the repair of
damaged muscle fibers in postembryonic life. Skeletal muscle
differentiation is a multistep process, in which mononucleated
myoblasts withdraw from the cell cycle, initiate the expression
of muscle genes, and fuse with each other to form the multinu-
cleated myotubes. This process is mostly orchestrated by the
MyoD family (MyoD, Myf5, myogenin, and MRF4) and MEF2
family (MEF2A-D) transcription factors (Molkentin and Olson,
1996; Weintraub et al., 1989). Their stage-specific associations
with different transcriptional coregulators ultimately activate
the differentiation program by inducing transcription of regula-
tory and structural muscle-specific genes (Caretti et al., 2006;
Deato et al., 2008; Tapscott, 2005). The unique feature of skeletal
muscle, the multinucleated syncytium structure (Horsley
and Pavlath, 2004; Richardson et al., 2008), however, raises192 Developmental Cell 20, 192–205, February 15, 2011 ª2011 Elseva question: is muscle cell fusion just part of the MyoD- and
MEF2-activated differentiation program? Or, is there a signaling
pathway, which is activated independently of the MyoD and
MEF2 activities, but plays a role in muscle cell fusion? Answering
these questions would shed light on the mechanism of how cells
control and coordinate gene expression to establish the tissue
specific phenotypes.
The mitogen-activated protein kinase (MAPK) cascades play
an essential role in connecting extracellular stimuli to the
changes in transcriptional programs. To date, at least four
MAP kinase pathways have been identified: the extracellular
signal-regulated kinase (ERK) 1/2 pathway, the c-Jun amino-
terminal kinase (JNK) pathway, the p38 pathway, and the
ERK5 pathway (Chang and Karin, 2001; Nishimoto and Nishida,
2006; Robinson andCobb, 1997). Each cascade plays a complex
pleiotropic role in different cell lineages and regulates a wide
variety of cellular functions. In skeletal muscle, the p38, ERK1/
2, and ERK5 pathways have been implicated in differentiation.
The p38 pathway is shown to promote the differentiation
process, and the mechanisms by which p38 activation regulates
the myogenic program have been well described (Gillespie et al.,
2009; Lluı´s et al., 2006; Penn et al., 2004; Rampalli et al., 2007;
Simone et al., 2004). On the other hand, the roles of the ERK1/
2 and ERK5 pathways have not been clearly demonstrated;
both positive and negative roles have been suggested (Dinev
et al., 2001; Koyama et al., 2008; Rommel et al., 1999; Wu
et al., 2000; Yokoyama et al., 2007). One possible explanation
for this discrepancy would be that the drug inhibitors of the
ERK1/2 pathway also could prevent the ERK5 pathway (Kama-
kura et al., 1999; Mody et al., 2001).
In this study, we have first focused on the role of the ERK1/2
and ERK5 pathways in skeletal muscle differentiation, and
revealed that the ERK5 pathway plays a crucial role in muscle
cell fusion. Subsequent analyses have then identified Sp1
and Klf2/4 transcription factors as essential factors through
which ERK5 regulates muscle cell fusion. Furthermore, our
analysis has identified several Klf transcriptional targets required
for muscle cell fusion. Importantly, the identified ERK5/Klf
signaling module is largely independent of the expression of
MyoD, MEF2, and their target genes, and vice versa. Therefore,
the ERK5/Klf pathway is specific for the fusion process in the
whole differentiation program, and is separable from other
events in the differentiation process, such as cell cycle with-
drawal and the expression of muscle-specific structural proteins
and enzymes.ier Inc.
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ERK5 Plays an Essential Role in Muscle Cell Fusion
To examine individual roles of ERK1/2 and ERK5, we employed
a mouse C2C12 skeletal muscle cell line, the well-established
in vitro differentiation model. In C2C12 cells, proliferating
myoblasts can be induced to differentiate at confluence by with-
drawal of serum, and most cells begin to fuse after 2–3 days and
form mature myotubes by 5 days. While ERK1/2 activity was not
altered after serumwithdrawal, ERK5 activity was increased and
sustained during terminal differentiation (Figure 1A). We used the
two different MEK inhibitors, U0126 and PD184352, which have
different specificities (Mody et al., 2001), and added each of
them to C2C12 cells before the initiation of fusion after serum
withdrawal. The addition of 20 mM U0126 immediately before
the onset of muscle cell fusion, which inhibited both the ERK1/
2 and ERK5 activities (Figure 1B), almost completely blocked
myotube formation and generated a large number ofmononucle-
ated myocytes (Figure 1C). However, U0126 treatment had little
effect on the expression of early (myogenin) and late myogenic
markers (myosin heavy chain, MyHC) (Figure 1B). Similar effects
on muscle differentiation were found in experiments with an
earlier treatment with U0126, in which the drug was added
immediately after the shift in the differentiation medium (see
Figures S1A–S1C available online). Thus, these U0126-treated
myocytes normally underwent the myogenic program except
for the fusion process. Then we exposed C2C12 cells to 2 mM
PD184352 that specifically inhibits the ERK1/2 pathway without
affecting the ERK5 pathway (Figure 1B). Treatment with
PD184352 did not suppress myotube formation or the expres-
sion of myogenin and MyHC (Figures 1B and 1C). These results
taken together suggest that while the ERK1/2 pathway is not
significantly involved in skeletal muscle differentiation, the
ERK5 pathway has an essential role in muscle cell fusion.
To selectively inhibit the ERK5 pathway, we expressed domi-
nant-negative MEK5 (dnMEK5) with adenovirus in C2C12 cells.
MEK5 is an ERK5 activator that specifically phosphorylates
and activates ERK5, and dnMEK5 is a nonphosphorylatable
mutant, which cannot be activated and thus acts dominant-
negatively (Kamakura et al., 1999). The expression of dnMEK5
inhibited ERK5 activity without affecting ERK1/2 activity (Fig-
ure 1D), as expected. The infection of the dnMEK5 virus at 1 or
2 day after serum withdrawal markedly suppressed muscle cell
fusion (Figure 1E). While ERK5-inhibited cells displayed thin
and elongated morphologies like myotubes, most of them
remained mononucleated. ERK5 inactivation did not attenuate
expression of muscle-specific genes, including MyoD, Mef2a,
p21, MyHC, and muscle creatine kinase (MCK), although
myogenin and Mef2c levels appeared to decline slightly at
6 days (Figures 1D and 1F). siRNA-mediated knockdown of
MEK5 or ERK5, in which siRNA transfection was done 1 day
before the shift in the differentiation medium, gave essentially
the same results as dnMEK5 expression (Figures S1F–S1H).
Then we examined the effect of expression of constitutively
active MEK5 (caMEK5) on the differentiation of C2C12 cells.
Adenoviral delivery of caMEK5 enhanced ERK5 activity without
affecting ERK1/2 activity (Figure 2A). The enhancement of
ERK5 activity facilitated muscle cell fusion and generated larger
myotubes with more nuclei than control cells (Figure 2B). AnDevelopmearlier delivery of caMEK5 gave essentially the same results
(Figure S1D). These large myotubes often appeared as rounded,
disorganized cells. Expression levels of muscle-specific genes in
ERK5-activated cells were, however, similar to those in the
control (Figures 2A and 2C; Figure S1E). Collectively, these
results strongly suggest that the ERK5 pathway is involved in
the regulation of muscle cell fusion with marginal effects on the
expression of muscle-specific genes.
The role of the ERK5 pathway in muscle differentiation was
also evaluated using satellite cells isolated from gastrocnemius
muscles of adult mice. Proliferating satellite cells can be induced
to proceed with later stages of the differentiation process by
serum withdrawal, and most cells form mature myotubes by
2 days. While treatment with the ERK1/2 pathway specific inhib-
itor PD184352 did not significantly affect myotube formation,
treatment with U0126, the inhibitor for both the ERK5 and
ERK1/2 pathways, impaired muscle cell fusion (Figure S2A),
indicating that the ERK5 pathway is involved in muscle cell
fusion. To selectively inhibit the ERK5 pathway, we expressed
dnMEK5 with adenovirus in satellite cells. In fact, dnMEK5
expression almost completely inhibited the activated ERK5
activity in satellite cells (Figure S2B). The ERK5 inhibition with
dnMEK5 significantly suppressed muscle cell fusion with little
effect on the expression of muscle-specific genes (Figures
S2B–S2D). Therefore, these results suggest that ERK5 plays
an important role in muscle cell fusion in both C2C12 cells and
primary muscle satellite cells. ERK5 knockout mice are embry-
onic lethal due to multiple developmental defects (Yan et al.,
2003). Therefore, it is difficult to demonstrate in vivo role of
ERK5 in muscle cell fusion. During embryogenesis, however,
both ERK5 and MEK5 are expressed in developing mouse
somites and limb buds, in both of which muscle cell fusion
occurs (Yan et al., 2003). This result suggests the possible
involvement of the ERK5 pathway in muscle cell fusion.
ERK5-Dependent Upregulated Genes Do Not Overlap
with theDownstreamTarget Genes ofMyogenic Factors
To identify those geneswhose expression levels are regulated by
the ERK5 pathway in differentiating C2C12 cells, we performed
the genome-wide analysis by using Affymetrix GeneChip oligo-
nucleotide microarrays, which contain over 39,000 transcripts
and variants, including about 20,000 well-substantiated mouse
genes. We used five samples (Figure 3A, upper panel): cells in
GM (0 day), lacZ-infected cells at two time points (2.5 and
4.5 days) and dnMEK5-infected cells at two time points (2.5
and 4.5 days). Each virus was infected at day 1. We identified
189 genes (208 probe sets) as ERK5-dependent upregulated
genes: their expression level in lacZ-infected (control) cells either
at 2.5 or at 4.5 days after serum withdrawal was increased by
1.5-fold or more, as compared with the expression level at the
start of differentiation (0 day), and the degree of the increase
was reduced by more than 50% in cells expressing dnMEK5
with statistical significance in replicate experiments (Figure 3A,
lower panel). Notably, the identified ERK5 pathway-regulated
genes for the most part do not overlap with the direct target
genes of myogenic factors previously identified by other investi-
gators (Blais et al., 2005) (Figures S3A and S3B), strongly
suggesting that the ERK5 pathway does not significantly affect
the MyoD- and MEF2-activated differentiation program.ental Cell 20, 192–205, February 15, 2011 ª2011 Elsevier Inc. 193
0 12 24 30 36 42 48 54 12
060 66 72 78 90 9684 10
2Hour 6 18 108114 144
1 2 3 4 5 60Day
Myogenin
MyHC
α-Tubulin
P-ERK5
ERK5
Day
2 3 4 5P-ERK5
ERK5
2 3 4 5
dnMEK5
(1d)
Myogenin
MyHC
0 1 6 2 3 4 5 66 3 4 5 6
lacZ
(1d)
dnMEK5
(2d)
lacZ
(2d)
A
D
%
of
nu
cl
ei
dnMEK5(1d)
lacZ(1d) lacZ(2d)
dnMEK5(2d)
P-ERK5
ERK5
0 1 2 3 4 5 3 4 5 3 4 5
C U PD
Myogenin
MyHC
Day
control U0126
PD184352
%
of
nu
cl
ei
B C
E
0
10
20
30
40
50
60
70
2-6
1
7-14
15<
0
10
20
30
40
50
60
70
80
2-6
1
7-14
15<
lacZ
(2d
)
lacZ
(1d
)
con PDU
F
P-ERK1
P-ERK2
ERK1
ERK2
P-ERK1
P-ERK2
ERK1
ERK2
Time (h)
0
0.1
0.2
0.3
P
-E
R
K
5
/t
ot
al
E
R
K
5
0 24 48 72 96 120 144
MyoD
p21
Mef2a Mef2c
MCK
lacZ
dnMEK5
R
el
at
iv
e
R
N
A
le
ve
l
R
el
at
iv
e
R
N
A
le
ve
l
DayDay
DayDayDay
0
1
2
3
4
0 2 4 6 0
2
4
6
0 2 4 6 0
40
80
120
160
200
0 2 4 6
0
40000
80000
0 2 4 60
4
8
12
16
0 2 4 6
dnM
EK
5(1
d)
dnM
EK
5(2
d)
Figure 1. ERK5 Activity Is Required for Muscle Cell Fusion in Skeletal Muscle Differentiation
(A) C2C12 cells were placed in the differentiation medium (DM) and incubated for the indicated times. The cells were harvested with lysis buffer, and equal
amounts of cell lysates were subjected to immunoblotting with the indicated antibodies. An upshifted band detected by anti-ERK5 antibody is a phosphorylated,
activated form of ERK5 (Mody et al., 2001). Representative data of two independent experiments are shown (left). The amounts of phosphorylated ERK5 were
quantified (right).
(B and C) C2C12 cells were placed in DM, and the indicated inhibitors were added after 2 days of differentiation. The inhibitors were replaced by fresh com-
pounds every 24 hr. C, DMSO (control); U, U0126 (20 mM); PD, PD184352 (2 mM). (B) Samples were collected at the indicated time points, and processed for
immunoblotting with the indicated antibodies. (C) Cells were fixed and immunostained for MyHC after 5 days of differentiation (left panel), and then quantified
for the percentage of MyHC+ nuclei present in myotubes with the indicated number of nuclei (right panel). Values represent means (±SD) in triplicate
determinations.
(D–F) C2C12 cells were infected with adenovirus containing lacZ or dnMEK5 at the time points indicated in parentheses. (D) Samples were collected at the
indicated time points, and processed for immunoblotting with the indicated antibodies. (E) Cells were fixed and immunostained for MyHC after 6 days of
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Figure 2. Forced Enhancement of ERK5 Activity Promotes Muscle Cell Fusion
(A–C) C2C12 cells were infected with adenovirus containing lacZ or caMEK5 after 1 day of differentiation.
(A) Samples were collected at the indicated time points and processed for immunoblotting with the indicated antibodies.
(B) Cells were fixed and immunostained for MyHC after 6 days of differentiation (left panel), and then quantified for the percentage of MyHC+ nuclei present in
myotubes with the indicated number of nuclei (right panel). Values represent means (±SD) in triplicate determinations.
(C) The cells were collected at the indicated time points, and the relative levels of mRNA of muscle-specific genes were determined by RT-PCR analysis. Values
represent means (±SD) in duplicate determinations.
See also Figure S2.
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To find the transcription factors involved in the expression of
these ERK5-dependent upregulated genes, we first used a de
novo motif-finding algorithm Weeder (Figure 3B). Consistent
with our finding that the ERK5 pathway inhibition has little effect
on the MyoD- and MEF2-dependent transcription events (see
above), theMyoD-orMEF2-binding consensusmotifs (Molkentin
and Olson, 1996) were not detected in any of the high-ranking
motifs of ERK5-dependent upregulated 189 genes. Instead, we
noticed that the high-rankingmotifs frequently include ‘‘CACCC’’
or ‘‘GGGTG,’’ which is known as the consensus sequence for Klf
transcription factors (Pearson et al., 2008). Then, we confirmed
that the 5 base motif CACCC or GGGTG is actually overrepre-
sented in the promoters of ERK5-dependent upregulated genes
(One-sided Fisher test, p = 3.9 3 106 compared with the
promoters of all genes) (Figure 3C). Remarkably, Klf2, Klf3, Klf4,
and Klf6 were also included in the ERK5-dependent upregulateddifferentiation (upper panel), and then quantified for the percentage ofMyHC+ nuc
represent means (±SD) in triplicate determinations. (F) Cells were collected at the
were determined by RT-PCR analysis.
Values represent means (±SD) in duplicate determinations.
Developmgenes (Figure 3A, lower panel; Figure S4A).We then analyzed the
expression patterns of Klf family genes during C2C12 differentia-
tion by quantitative RT-PCR, and the obtained results (Fig-
ureS4B) are in good agreementwith ourmicroarray data. In these
Klf family genes, we focused on Klf2 and Klf4, as the expression
levels of these two genes were increased by more than 4-fold at
2.5 and 4.5 days, compared with those at 0 day, during differen-
tiation, and these increases were almost completely blocked by
the ERK5 inhibition. The prominent reduction of Klf2 and Klf4
expression by the ERK5 pathway inhibition during C2C12 differ-
entiation was commonly observed in all of the experiments with
U0126 treatment, dnMEK5 expression, or MEK5 or ERK5-tar-
geted siRNA treatment (Figures S1C and S1H; Figure 4A).
To investigate the effect of loss of Klf2 or Klf4 expression on
muscle differentiation, C2C12 cells were transfected with
siRNAs designed specifically for Klf2 or Klf4. Cells transfected
with Klf2si#2, Klf4si#1, or Klf4si#2 showed reduced expressionlei present inmyotubes with the indicated number of nuclei (lower panel). Values
indicated time points, and the relative levels of mRNA of muscle-specific genes
ental Cell 20, 192–205, February 15, 2011 ª2011 Elsevier Inc. 195
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Figure 3. The Expression Profile and Promoter Analysis of ERK5-Dependent Upregulated Genes
(A) Expression profiles of ERK5-dependent upregulated genes (208 probe sets, 189 genes) are shown. Each horizontal line displays the expression data for one
probe set, where the ratio of mRNA level to its level in the cells in GM is represented by color according to the color scale at the bottom.
(B) The promoter sequence (1.0 to +0.2 kb) of each gene was extracted from the database of experimentally determined transcriptional-start sites (DBTSS v5.0
(Suzuki et al., 2004)). The 140 promoters of ERK5-dependent upregulated genes were scanned by Weeder v1.3 (Pavesi et al., 2001). The motifs containing the
Klf-binding site are emphasized with red. The sequence logo was created with enoLOGOS (Workman et al., 2005).
(C) To prove the enrichment of ‘‘CACCC’’ or ‘‘GGGTG,’’ the occurrences of all 5 base motifs in the promoter sequences were counted. Repeat sequences were
masked. For each 5 base motif, the distribution of hits in the 140 promoters was compared with that in all 13,704 promoters. Among all 512 motifs, CACCC or
GGGTG showed the second highest significance.
(D) The 140 promoters of ERK5-dependent upregulated genes were scanned with MATCH v10.4 (Kel et al., 2003) using 566 vertebrate position weight matrices
(cutoff = minFP). For each matrix, the distribution of hits in the 140 promoters was compared with that in all genes. The P-values are from one-sided Fisher tests.
See also Figure S3.
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ERK5 Regulates Muscle Cell Fusionof Klf2 or Klf4 (Figure 4B). Klf4 protein levels, which were mark-
edly increased after serum withdrawal, were also markedly
reduced in cells transfected with Klf4si#1 or Klf4si#2 (Figures
S4C and S4D). Knockdown of Klf2 or Klf4 by these siRNA
resulted in thinner and smaller myotubes with fewer nuclei,
compared with those formed in cells transfected with GFP
siRNA, Klf2si#1, a noneffective siRNA or mock-transfected cells
(Figure 4D). Ectopic expression of Klf4 in the Klf4si#1-
transfected cells restored muscle cell fusion (Figure 4E). Klf4si#1
is targeted to the 30 untranslated region of Klf4 mRNA, and
therefore the Klf4 expression vector should be resistant to
Klf4si#1-mediated silencing. In addition, we have also found
that overexpression of Klf2 and Klf4 in control cells promoted
muscle cell fusion and generated larger myotubes with more
nuclei (Figure 4F). These results taken together demonstrate
that Klf2 and Klf4 play an essential role in muscle cell fusion. It
should be also noted that sustained ERK5 activation during
differentiation seems to be necessary for stable expression of
Klf proteins, because the addition of U0126 resulted in the rapid
decrease in the Klf4 protein level (Figure S4E). Importantly,
knockdown of Klf2 or Klf4 did not suppress the expression of
muscle differentiation marker genes (Figure 4C). Thus, Klf2 and
Klf4 transcription factors are specifically required for muscle
cell fusion, probably as the downstream effectors of ERK5. In
primary satellite cells, Klf2 and 4 mRNA levels are already high196 Developmental Cell 20, 192–205, February 15, 2011 ª2011 Elsevat the onset of differentiation (Figure S2D). This result is consis-
tent with the observation that the expression of muscle differen-
tiation marker genes is already detectable at 0 day (Figure S2D).
ERK5 inhibition significantly reduced the expression level of Klf2,
although Klf4 expression was not affected (Figure S2D). There-
fore, Klf2 expression may be under control of the ERK5 pathway
in satellite cells, as in C2C12 cells. Klf4 expression may be
controlled in a different way.
The ERK5/Klf Pathway Is Activated Independently
of the MyoD and MEF2 Activities
To gain insight into the mechanism by which the ERK5/Klf
pathway is activated in C2C12 cells, we used several growth
factors that are known to affect myogenesis. Basic fibroblast
growth factor (bFGF) and bone morphogenic protein 2 (BMP2),
both of which are known to block myogenesis (Katagiri et al.,
1994; Salminen et al., 1991), did in fact block the expression of
muscle-specific genes, but did not significantly inhibit ERK5
activity (Figure 5A). Insulin-like growth factor 1 (IGF1), which is
known to stimulate myogenic program (Coleman et al., 1995),
did in fact promote the expression of muscle genes, but did
not enhance ERK5 activity (Figure 5A). Also, ectopically ex-
pressed MyoD in C3H10T1/2 fibroblasts did not enhance
ERK5 activity (data not shown). Furthermore, the inhibition of
expression of myogenic factors by BMP2 did not reduce Klf2/4ier Inc.
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ERK5 Regulates Muscle Cell Fusionexpression (Figure 5B). Therefore, the ERK5/Klf pathway is acti-
vated during muscle differentiation, independently of the activi-
ties of MyoD and MEF2 family transcription factors. Importantly,
although ERK5 activity remained at a high level in BMP2- or
bFGF-treated cells, in which the activities of myogenic factors
were inhibited, cell fusion was completely blocked (Figure 5C,
upper panel). Furthermore, the treatment with BMP2 or bFGF
immediately before the onset of muscle cell fusion almost
completely blocked the expression of muscle differentiation
marker genes and myotube formation, suggesting the absolute
requirement of the activities of myogenic factors for muscle
cell fusion (Figure 5C, lower panel, and 5D). Moreover, ectopic
induction of ERK5 activity or Klf2/4 expression in C3H10T1/2
cells which lack myogenic factors did not induce cell fusion
(data not shown). Interestingly, however, even though Klf2/4
expression is not directly regulated by ERK5 activity (data not
shown), knockdown of endogenous Klf4 blocked the fusion of
MyoD-transduced C3H10T1/2 cells (Figures S5A and S5B).
Conversely, overexpression of Klf factors prominently enhanced
MyoD-induced myotube formation of C3H10T1/2 cells (Fig-
ure S5C). These results taken together suggest that the activa-
tion of the ERK5/Klf pathway alone is unable to induce cell
fusion, and that both the ERK5/Klf pathway and the activities
of myogenic factors are necessary for muscle cell fusion.
Sp1 Transcription Factor Is a Key Molecule Linking
ERK5 to Klf2/4 and Plays an Essential Role in Muscle
Cell Fusion
To identify a molecule linking ERK5 activation to Klf2/4 expres-
sion, we performed promoter analysis using the TRANSFAC
database (Kel et al., 2003), which catalogs vertebrate transcrip-
tion factors and their known binding sites. Our analysis using 566
TRANSFACmatrices have revealed that Sp1-binding sites (Kac-
zynski et al., 2003) are among the overrepresented matrices in
the promoter regions of ERK5-regulated genes (Figure 3D),
and thus suggested that Sp1 transcription factor is a possible
downstream effector of ERK5. The overrepresentation of the
Klf motif was not found here because the TRANSFAC version
10.4 used in this analysis does not contain the information about
the Klf motif. On the other hand, the Sp1 motif was not found by
the algorithm of Weeder (Figure 3B). Sp1 has been shown to
directly regulate the expression of Klf2 and Klf4 (Deaton et al.,
2009; Schrick et al., 1999). Furthermore, the MAPK family
members, ERK1/2 and p38, are shown to phosphorylate and
activate Sp1 (D’Addario et al., 2006; Tan and Khachigian,
2009), although the interaction between ERK5 and Sp1 has not
previously been identified. Then, we first examined whether
Sp1 is a target of ERK5. The expression of dnMEK5 or siRNA-
mediated knockdown of MEK5 or ERK5 did not significantly
affect Sp1 expression levels, although in dnMEK5-infected cells
the amount of Sp1 protein decreased at 4 or 5 days after adeno-
viral infection (Figure 6A). In reporter assays with the reporter
plasmid, in which the luciferase reporter gene is driven by the
Sp1 consensus element, the activation of the ERK5 pathway
by expressing ERK5WT and caMEK5 resulted in more than
5-fold increases of the Sp1-dependent reporter gene expression
over the control (Figure 6B). Expression of ERK5WT plus
dnMEK5 or dnERK5 (a nonactivatable form of ERK5 (ERK5AEF)
(Kato et al., 1997) that acts dominant-negatively) plus caMEK5Developmdid not stimulate the Sp1 activity (Figure 6B). These results
suggest that the ERK5 pathway activates Sp1 activity. Next,
we examined whether Sp1 regulates the expression of Klf2
and Klf4. As three and four Sp1-binding sites exist in the Klf2
promoter and theKlf4 promoter regions, respectively (Figure 6C),
we performed ChIP assays using anti-Sp1 antibody. The results
have shown that Sp1 binds to the promoter regions of both Klf2
and Klf4, but not to the intron regions of them (Figure 6D). More-
over, siRNA-mediated knockdown of Sp1 severely reduced
mRNA levels of Klf2 and Klf4 (Figures 6E and 6F). These results
therefore show that Sp1 is a direct activator of Klf2/4 expression.
The expression of muscle genes including MyHC, myogenin,
MCK, and p21, which have no putative Sp1-binding site in the
promoter regions, was not downregulated by Sp1 knockdown
(Figure 6E and data not shown). On the other hand, even though
the promoter regions of MyoD, Mef2a, and Mef2c contain one
putative Sp1-binding site, Sp1 knockdown did not attenuate
expression of these genes (data not shown), suggesting that
the number of Sp1 consensus elements is important and just
one binding site is not sufficient for its physiological activity.
Importantly, Sp1 downregulated cells produced thinner and
smaller myotubes with fewer nuclei than those formed in cells
transfected with mock-siRNA, GFPsiRNA, or a noneffective
siRNA (Figure 6G). These results collectively demonstrate that
Sp1 transcription factor is a key molecule linking ERK5 to Klf2/
4 and plays an essential role in muscle cell fusion.
Nephronectin Is a Klf Transcriptional Target and
Involved in Muscle Cell Fusion
Remarkably, forced expression of Klf2 and Klf4 in the ERK5-in-
hibited cells significantly restored muscle cell fusion (Figure 7A).
Klf2 and Klf4 expression did not alter the inhibited ERK5 activity
(Figure 7B). Thus, these results also support our conclusion that
Klf2 and Klf4 lie downstream of ERK5 in a signaling pathway,
which regulates muscle cell fusion. Then we examined in more
detail the functional role of the ERK5/Klf transcription factors
pathway in the fusion process. To identify genes that play
a role in the fusion process, we searched the ERK5-dependent
upregulated 189 genes and found an adhesionmolecule nephro-
nectin (Npnt) as a candidate gene; the induced expression of
Npnt during muscle differentiation was almost completely
blocked by the ERK5 inhibition (see Figure 3A). Quantitative
RT-PCR analysis confirmed the array data (Figure 7C). siRNA-
mediated knockdown of Klf2 and Klf4 markedly suppressed
the induced expression of Npnt (Figure 7D). Cells transfected
with Npnt siRNA (si#1) showed a markedly reduced expression
level of Npnt, and generated smaller myotubes with fewer nuclei
than those formed in cells transfected with luciferase siRNA
(Figures 7E and 7F), indicating that Npnt is required for efficient
muscle cell fusion. Thus, our analysis has identified Npnt as
a important player involved in muscle cell fusion. As Npnt is
a matrix protein involved in cell-matrix adhesion (Brandenberger
et al., 2001), Npnt would facilitate the fusion process by
promoting cell-matrix adhesion, which is thought to be essential
for muscle cell fusion. Moreover, it has been reported that b1
integrin, a well-known regulator of muscle cell fusion, associates
with Npnt in kidney (Brandenberger et al., 2001). Thus, the inter-
action of Npnt with b1 integrin in myoblasts is likely to be impor-
tant for muscle cell fusion.ental Cell 20, 192–205, February 15, 2011 ª2011 Elsevier Inc. 197
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Figure 4. Klf2 and Klf4 Are Required for Muscle Cell Fusion
(A) C2C12 cells were infected with adenovirus containing lacZ or dnMEK5 after 1 day of differentiation. The cells were collected at the indicated time
points, and the relative levels of Klf2 mRNA and Klf4 mRNA were determined by RT-PCR analysis. Values represent means (±SD) in duplicate determina-
tions.
(B–D) C2C12 cells were transfected with siRNAs targeted against GFP, Klf2, or Klf4. After 24 hr, the medium was replaced with DM. For each gene, two
independent siRNAs were designed to target different parts of mRNA. Mock, no siRNA but with transfection reagent. (B) The cells were collected at the indicated
time points, and the relative mRNA levels of Klf2 and Klf4 were examined by RT-PCR analysis. Values represent means (±SD) in duplicate determinations. (C) The
cells were collected at the indicated time points, and processed for immunoblotting with the indicated antibodies. (D) Cells were fixed and immunostained for
MyHC after 5 days of differentiation (upper panel), and then quantified for the percentage of MyHC+ nuclei present in myotubes with the indicated number of
nuclei (lower panel). Values represent means (±SD) in triplicate determinations.
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ERK5 Regulates Muscle Cell FusionInterestingly, several known fusion regulators (Richardson
et al., 2008), including Cd164, Cd9, Cdh15, Ehd2, and Vcam1,
were downregulated by the ERK5 inhibition (Figure S3D). In
these genes, Cdh15, an adhesion molecule required for muscle
cell fusion (Charrasse et al., 2007), satisfies our criteria for ERK5-
dependent upregulated genes. Our quantitative RT-PCR
measurement confirmed that the induced expression of Cdh15
during differentiation was suppressed by the ERK5 inhibition
with dnMEK5 (Figure 7C). Furthermore, siRNA-mediated knock-
down of Klf2 and Klf4 downregulated the expression level of
Cdh15 slightly but reproducibly (Figure 7D), suggesting that the
ERK5/Klf pathway regulates muscle cell fusion in part through
the induction of Cdh15.
We then performed ChIP assays to determine whether Npnt
and Cdh15 are direct transcriptional targets of Klf2 or Klf4. Eight
and twoCACCCmotifs exist in theNpnt promoter and the Cdh15
promoter regions, respectively (Figure 7G; Figure S3C). The
results showed that both Klf2 and Klf4 bound to the promoter
region of Npnt, but not to that of Cdh15 (Figure 7H, upper panel
and data not shown). Klf2 and Klf4 did not bind to the promoter
region of formin1 (Figure 7H, lower panel), which is included in
the ERK5-upregulated genes but has no Klf-binding sites in its
promoter. In reporter assays with the reporter plasmid, in which
the luciferase reporter gene is driven by the Npnt promoter,
expressionofKlf2 orKlf4 resulted inmore than300-fold increases
of the luciferase activities over the control (Figure 7I). In contrast,
the Fmn1 promoter activity was not affected (Figure 7I). These
results taken together suggest that Npnt is a direct transcriptional
target of Klf2 and Klf4. We observed that the extents of inhibition
of muscle cell fusion by the inhibition of each component of the
MEK5/ERK5/Klf2/4/Npnt pathway in collagen-coated dishes
were almost the same as those in uncoated plastic dishes
(Figures S6A–S6I). In addition, siRNA-mediated knockdown of
ERK5, Klf2/4, or Npnt significantly reduced the impact of the
forced enhancement of ERK5 activity on muscle cell fusion (Fig-
ure S6J), suggesting that MEK5, ERK5, Klf2/4, and Npnt lie in the
same signaling pathway required for muscle cell fusion.
DISCUSSION
Here, we have identified the ERK5 signaling pathway through
Sp1 and Klf2/4 transcription factors as an essential signaling
cascade for muscle cell fusion. Our genome-wide analysis has
shown that the inhibition of the ERK5 pathway has marginal
effects on the expression of the transcriptional target genes of
MyoD and MEF2 families (Figures 1–3). The earlier inhibition of
the ERK5 pathway gave essentially the same results as the later
inhibition, although the effect on the expression of muscle
marker genes was a little bit stronger than that of the later inhibi-
tion (Figure S1). This observation is consistent with the previous(E) C2C12 cells were transfected with mock siRNA (no siRNA but with transfect
or CSII-EF-HA-Klf4-IRES-EGFP (Klf4). After 24 hr, cells were allowed to differentia
(left panel), and then quantified for the percentage of MyHC+ nuclei present in m
means (±SD) in duplicate determinations.
(F) C2C12 cells were infected with CSII-EGFP (GFP) or CSII-EF-HA-Klf2-IRES-E
allowed to differentiate. Cells were fixed and immunostained for MyHC after 5
MyHC+ nuclei present in myotubes with the indicated number of nuclei. (right pa
See also Figure S4.
Developmreport (Dinev et al., 2001), in which C2C12 cells stably express-
ing ERK5AEF (a dominant-negative form of ERK5) or antisense-
ERK5 exhibited attenuated expression of MyoD, myogenin, and
p21. Importantly, our results have demonstrated that the inhibi-
tion of the ERK5 pathway has a dramatic inhibitory effect on
muscle cell fusion despite the small attenuation of the muscle-
specific genes. Our subsequent analyses have then revealed
that Sp1 and Klf family of transcription factors mediate the effect
of the ERK5 pathway on muscle cell fusion. Collectively, our
results suggest that the contribution of ERK5 to the expression
of MyoD, MEF2, and their downstream genes is small, and that
the main targets of ERK5 in the context of myogenesis are Sp1
and Klf family transcription factors, which regulate expression
of genes involved in muscle cell fusion. It should be noted that
both the ERK5/Klf pathway and the myogenic factors are essen-
tial for muscle cell fusion, as the activation of the ERK5/Klf
pathway alone is unable to induce cell fusion.
There were some differences between MyoD-expressing
10T1/2 cells and C2C12 cells. The ERK5 pathway is not acti-
vated during differentiation of the MyoD-converted 10T1/2 cells
(data not shown). Probably, some unknown factors which are
intrinsic to myogenic cells but not regulated by MyoD would be
involved in ERK5 activation. MyoD-expressing 10T1/2 cells
undergo fusion even with low ERK5 activity. This may be
because the expression of Klf factors is not mediated by the
ERK5 pathway in 10T1/2 cells (data not shown). Indeed, 10T1/
2 cells express Klfs in spite of low ERK5 activity, and knockdown
of endogenous Klf4 blocked MyoD-induced myotube formation
of 10T1/2 cells (Figures S5A and S5B). Conversely, overexpres-
sion of Klf2/4 prominently enhanced the cell-cell fusion in the
MyoD-converted 10T1/2 cells (Figure S5C). Thus, even though
both MyoD and Klf factors are necessary for the fusion of
10T1/2 fibroblasts, Klf expression may be regulated by the
mechanism different from that in C2C12 cells. It remains unclear
why the expression of Klfs is not mediated by the ERK5/Sp1
pathway in 10T1/2 cells. One possible interpretation is that the
amounts of ERK5 and/or Sp1 are not sufficient to activate Klf
loci in 10T1/2 cells. Indeed, 10T1/2 cells express relatively small
amounts of ERK5 and Sp1 compared with C2C12 cells (data not
shown).
Many regulators for cell fusion have recently been identified.
Most of these genes were not downregulated when the ERK5
activity was inhibited (Figure S3D). Probably, other upstream
factors, such as myogenic factors or transcriptional regulators
required for muscle cell fusion (Bois and Grosveld, 2003; Horsley
et al., 2001), may be involved in the expression of these fusion
regulators. However, several of these genes were downregu-
lated by the ERK5 inhibition (Figure S3D). Furthermore, our anal-
yses have identified nephronectin, which is shown to be a direct
Klf transcriptional target, as an important player in muscle cellion reagents) or Klf4 si#1, and simultaneously infected with CSII-EGFP (GFP)
te. Cells were fixed and immunostained for MyHC after 5 days of differentiation
yotubes with the indicated number of nuclei. (right panel). Values represent
GFP plus CSII-EF-HA-Klf4-IRES-EGFP (Klf2 plus Klf4). After 24 hr, cells were
days of differentiation (left panel), and then quantified for the percentage of
nel). Values represent means (±SD) in duplicate determinations.
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Figure 5. Treatment with bFGF, BMP2, or IGF1 Affects Muscle Cell Fusion as well as MyoD and MEF2 Activities without Affecting ERK5
Activity
(A) C2C12 cells were incubated with bFGF (50 ng/ml), BMP2 (300 ng/ml), or IGF1 (100 ng/ml). The compounds were replaced every day along with the medium
changes. Control, nontreated. The cells were collected at the indicated time points, and processed for immunoblotting with the indicated antibodies (left panel).
The amounts of phosphorylated ERK5 were quantified (right panel).
(B) C2C12 cells treatedwith BMP2 (300 ng/ml) were collected at the indicated time points, and the relative levels ofmRNA of the indicated genes were determined
by RT-PCR analysis. Values represent means (±SD) in duplicate determinations.
(C) C2C12 cells were incubated with bFGF (50 ng/ml), BMP2 (300 ng/ml), or IGF1 (100 ng/ml) for the indicated time in parenthesis. Cells were fixed and immu-
nostained for MyHC after 5 days of differentiation (right panel). Cells were infected with adenovirus containing GFP after 2 days of differentiation (green), and
Nuclei were stained with Hoechst (blue) (left panel). Treatment with bFGF or BMP2 almost completely suppressed muscle cell fusion, whereas IGF1 treatment
promoted muscle cell fusion.
(D) C2C12 cells were placed in DM, and bFGF (50 ng/ml) or BMP2 (300 ng/ml) was added after 2 days of differentiation. Cells were collected at the indicated time
points, and the relative levels of mRNA of the indicated genes were determined by RT-PCR analysis. Values represent means (±SD) in duplicate determinations.
See also Figure S5.
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ERK5 Regulates Muscle Cell Fusionfusion. How do these factors regulate muscle cell fusion? Inter-
estingly, either U0126 treatment or knockdown of each compo-
nent of the identified signaling module (MEK5, ERK5, Sp1, or
Klf2/4) rapidly resulted in parallel alignment of highly spindle-
shaped C2C12 cells in our preliminary experiments (unpublished
observations). This may imply that the inhibition or knockdown of
each component of the identified MEK5/ERK5/Sp1/Klf2/4
pathway results in essentially the same phenotype regarding
cell shape, motility, and orientation. Conversely, overexpression
of Klf2/4 led to random orientation of polygonal cells, rather than
spindle-shaped cells (unpublished observations). These results
suggest that each component of this pathway in fact lies in the
same signaling pathway, which would regulate the fusion
process through the induction of genes controlling cell shape,
adhesion, and motility.
Our results have shown that the ERK5/Klf pathway is largely
independent of the expression of myogenic factors and their
target genes, and vice versa. The ERK5/Klf pathway regulates a
number of genes required for fusion, but these target genes alone
could not accomplish cell-cell fusion. Myogenic factors would
regulate a distinct set of fusion genes, and the expression of
both the ERK5/Klf pathway target genes and the myogenic
factors target genes should be required to successfully complete
the fusionprocess. Therefore, both theERK5/Klf pathway and the
activitiesofmyogenic factorsarenecessary formusclecell fusion.
The MyoD/MEF2 families and their coregulators alone would not
be sufficient for the accomplishment of myogenesis. Multiple
mechanisms, including the ERK5/Klf pathway, would be required
for muscle cell fusion that generates normal multinucleated myo-
tubes. Tight control of the fusion process throughmultiple mech-
anisms may be a strategy to prevent inappropriate cells from
fusing each other and forming abnormal, nonfunctional syncytia.
EXPERIMENTAL PROCEDURES
Materials and Antibodies
Fibroblast growth factor (FGF) basic, insulin-like growth factor 1 (IGF1), and
bone morphogenetic protein 2 (BMP2) were purchased from RD Systems.
Leukemia inhibitory factor was purchased from Almone labs. U0126 was
purchased from Promega, and PD184352 from Upstate Biotechnology. Anti-
bodies were purchased as follows; rabbit IgG (sc-2027), mouse anti-myogenin
(F5D), rabbit anti-ERK1 (K-23), and rabbit anti-HA (Y-11) antibodies from Santa
Cruz; mouse anti-a-tubulin (DM1A) and rabbit anti-ERK5 (E-1523) antibodies
from Sigma; mouse anti-MyHC (MF20) antibody from Developmental Studies
Hybridoma Bank; mouse anti-phospho-ERK1/2 (E10) antibody from Cell
Signaling; rabbit anti-Sp1 (07-645) antibody from Upstate Cell Signaling Solu-
tions. Alexa Fluor 488-goat anti-mouse IgG, Alexa Fluor-594 goat anti-mouse
IgG from Molecular Probes.
Cell Culture
C2C12 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 15% fetal bovine serum (FBS) (growth medium; GM). To induce
differentiation, growth mediumwas replaced with DMEM containing 3% horse
serum (differentiation medium; DM) when cells were 90%–100% confluent.
When cells were plated at 20,000 cells/cm2, the culture reached 90%–100%
confluence 24 hr later. Cells were replenished with fresh DM every 24 hr. All
the experiments were performed using cells from the same passage number.
The culture medium volumes are as follows; 0.5 ml for 24-well plate, 1.0 ml for
12-well plate, and 2.0 ml for 6-well plate.
Plasmids and Transfection
The cDNAs of mouse Klf2 and Klf4 were isolated fromC2C12 cells by PCR and
ligated into pcDNA3 containing HA tag. C2C12 cells were transfected by usingDevelopmLipofectamine Plus reagent (Invitrogen) according to the manufacturer’s
protocol. An Sp1 luciferase reporter vector was purchased from Panomics
(Cat# LR0071). The cDNAs for the mouse Npnt promoter (1000 to +84 bp)
and Fmn1 promoter (920 to +194 bp) were isolated from C2C12 cells by
PCR and ligated into the pGL3 luciferase reporter vector (Promega). The
primers used for PCR amplification are described in the Supplemental Exper-
imental Procedures.
Luciferase Assay
Cells split onto 12-well dishes were harvested for assay at 24 hr after transfec-
tion. The luciferase activity in cell lysateswasmeasured by the luciferase assay
system (Promega). To determine transfection efficiency, coexpressed
b-galactosidase activity was measured, and the data were normalized for
b-galactosidase activities.
Adenoviral Infection
AdV-CA-lacZ, adenovirus expressing b-galactosidase driven by the CAG
promoter, was a kind gift from S. Takada. Adenovirus expressing dominant-
negative MEK5 was a kind gift from H. Hirota. Dominant-negative MEK5 is
a nonphosphorylatable mutant, in which Ser-311 and Thr-315 were replaced
by Ala and Val, respectively (Kamakura et al., 1999). The adenovirus express-
ing constitutively active MEK5 was purchased from Cell Biolabs Inc. The dual
phosphorylation site S311/T315 in this mutant has been changed to D311/
D315 (Kamakura et al., 1999). The recombinant adenovirus was amplified
and purified by CsCl2 step-gradient centrifugation. For viral infection, purified
adenoviruses (1.73 108 ifu/ml or 3.43 108 ifu/ml) were added to the medium.
The efficiency of adenovirus infection was 80%90%, as determined by GFP
expression.
Lentivirus Infection
For the preparation of lentiviral vectors, we used the packaging vector pCAG-
HIVgp encoding HIV-1 viral proteins (Gag and Pol), the vesicular stomatitis
virus G glycoprotein- and Rev-expressing vector pCMV-VSV-G-RSV-Rev,
and the self-inactivating vector CSII-EF-MCS-IRES-EGFP (CSII-EGFP).
To produce recombinant lentiviruses, CSII-EGFP (control), CSII-EF-HA-Klf2-
IRES-EGFP, or CSII-EF-HA-Klf4-IRES-EGFP was cotransfected with pCAG-
HIVgp and pCMV-VSV-G-RSVRev into 293T cells using Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer’s protocol. Culture super-
natants containing viruses were collected 48 hr after transfection, and then
viruses were concentrated by ultracentrifugation. For viral infection, a growth
medium was replaced with a medium containing virus when C2C12 cells were
40%–60% confluent. After 24 hr, cells were washed and allowed to differen-
tiate. The efficiency of lentivirus infection was 90%100%, as determined
by GFP expression.
siRNA Experiments
siRNAs were transfected at a final concentration of 130 nM using Lipofect-
amine 2000 reagent (Invitrogen) according to the manufacturer’s protocol.
Transfection was performed when the cells were at 50%–60% confluence.
After 1 day, cells were washed and allowed to differentiate. Under this condi-
tion, the efficiency of siRNA transfection was more than 70%. The sequences
used for siRNA studies were described in the Supplemental Experimental
Procedures.
Immunostaining
Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline
(PBS) for 15min at room temperature and then permeabilized with 0.5% Triton
X-100 in PBS for 5 min. Cells were blocked with 3% bovine serum albumin in
PBS and incubated with anti-MyHC antibody (MF20), followed by incubation
with the appropriate secondary antibodies. The efficiency of fusion was deter-
mined as follows: MyHC positive cells were classified into four groups; singly
nucleated MyHC positive cells, cells containing 2 to 6 nuclei, cells containing 7
to 14 nuclei, and cells containing 15 and more nuclei. Then the number of
nuclei of cells in each group was counted, and divided by the total number
of nuclei of MyHC positive cells. At least 300 nuclei of MyHC positive cells
were counted for each treatment in each experiment. Fluorescence images
were examined with a laser scanning confocal microscope (Bio-Rad), Axio-
plan2 (Zeiss), or Axiovision (Zeiss).ental Cell 20, 192–205, February 15, 2011 ª2011 Elsevier Inc. 201
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Figure 6. Sp1 Transcription Factor Is a Key Molecule Linking ERK5 to Klf2/4 and Plays an Essential Role in Muscle Cell Fusion
(A) C2C12 cells were infected with adenovirus containing lacZ or dnMEK5 after 1 day of differentiation (left), or transfected with siRNAs targeted against MEK5
or ERK5 1 day prior to the induction of differentiation (right). Samples were collected at the indicated time points, and processed for immunoblotting with the
indicated antibodies. The amounts of Sp1 protein were quantified. The values were normalized to a-tubulin and relative to time zero.
(B) The indicated expression plasmids were transfected with the reporter vector, which contains two tandem Sp1 consensus elements, in C2C12 cells. The
medium was replaced with DM immediately. After 24 hr, cells were harvested and then lysates were subjected to the luciferase assay.
(C) The locations and sequences of the Sp1 consensus element in the promoter regions of Klf2 and Klf4 are shown.
(D) C2C12 cells were placed in DM. After 3 days, chromatin fragments of the cells were immunoprecipitated with control IgG or anti-Sp1 antibody. Immunopre-
cipitation of each promoter or each intron region was quantified by RT-PCR. The values of immunoprecipitation with control IgG were set to 1. Values represent
means (±SD) in quadruplicate determinations.
(E–G) C2C12 cells were transfectedwith siRNAs targeted against GFP or Sp1. After 24 hr, themediumwas replaced with DM. For Sp1 silencing, two independent
siRNAs were designed to target different parts of mRNA. (E) The cells were collected at the indicated time points, and processed for immunoblotting with the
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Cells were lysed in lysis buffer (20 mM Tris-Cl [pH 7.5], 2 mM EGTA, 1.5 mM
MgCl2, 150 mM NaCl, 10 mM NaF, 12.5 mM b-glycerophosphate, 1 mM phe-
nylmethylsulfonyl fluoride, 2 mM dithiothreitol, 17 mg/ml aprotinin, 1 mM vana-
date, and 1% Triton-X). The proteins were separated by SDS-PAGE and
analyzed by immunoblotting.
Quantitative RT-PCR
Total RNA was extracted using an RNeasy mini kit (QIAGEN) according to the
manufacturer’s instruction. Total RNAwas then reverse-transcribed into cDNA
by using Moloney murine leukemia virus reverse transcriptase (Invitrogen) with
oligonucleotide random hexamers. Prepared cDNA was purified and sub-
jected to quantitative PCR analysis by using ABI 7300 Real Time PCR System
(Applied Biosystems) with the SYBER Green PCR kit (QIAGEN). The values
were normalized to GAPDH and relative to time zero. The primers for the
PCR analysis are described in the Supplemental Experimental Procedures.
Microarray Experiments
For microarray analysis, we performed two independent experiments. For
each experiment, we used five samples: cells in GM (0 day), lacZ-infected cells
at two time points (2.5 and 4.5 days) and dnMEK5-infected cells at two time
points (2.5 and 4.5 days). Each virus was infected at day 1. Total RNA was
prepared using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s
instruction. The total RNA of each condition was obtained from two indepen-
dent experiments. Synthesis of cDNA, in vitro transcription and biotin labeling
cRNA, and hybridization to the Mouse Genome 430 2.0 array (Affymetrix) were
performed according to Affymetrix protocols.
Data Analysis
The affymetrix (CEL files) was imported into GeneSpring 7.3 (Agilent Technolo-
gies)microarray analysissoftware for statistical analysis andGeneSpring10.0.2
for presentation of the expression profiles. Probe intensities were normalized,
and expression signals of all genes (probe sets) were calculated using GCRMA
(GC robust multiarray analysis, as implemented in GeneSpring software).
ERK5-dependent upregulated genes were identified by fold-changes and
statistical analysis. Statistical analysis was performed by one-way ANOVA
with a Benjamini and Hochberg False Discovery Rate (BH-FDR = 0.1) for
multiple testing correction followed by Tukey’s post-hoc tests (GeneSpring).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as described before (Yama-
moto et al., 2006). Immunoprecipitated chromatin was quantified with real-
time PCR. The primers for PCR analysis are described in the Supplemental
Experimental Procedures.
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Figure 7. Nephronectin (Npnt) Is a Klf Transcriptional Target and Involved in Muscle Cell Fusion
(A and B) C2C12 cells were infected with CSII-EGFP (GFP) or CSII-EF-HA-Klf2-IRES-EGFP plus CSII-EF-HA-Klf4-IRES-EGFP (HA-Klf2 plus HA-Klf4). After 24 hr,
cells were allowed to differentiate. Then, 20 mMU0126 was added after 2 days of differentiation. (A) Cells were fixed and immunostained for MyHC after 5 days of
differentiation (left panel), and then quantified for the percentage of MyHC+ nuclei present in myotubes with the indicated number of nuclei (right panel). Values
represent means (±SD) in triplicate determinations. For unknown reason, we needed three times more exposure time (15 s) to produce similar levels of GFP
signals in Klf2 plus 4-expressed cells, compared with control cells.
(B) The cells were collected at the indicated time points, and processed for immunoblotting with the indicated antibodies.
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